S
Sven Mahner
Researcher at Ludwig Maximilian University of Munich
Publications - 545
Citations - 12728
Sven Mahner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 46, co-authored 439 publications receiving 9126 citations. Previous affiliations of Sven Mahner include Charité & University of Hamburg.
Papers
More filters
Journal ArticleDOI
Gesichtslähmung nach Gemini-Geburt
Julia Jückstock,Theresa Vilsmaier,Julian Koch,T. Marx,S. Wenninger,Sven Mahner,Ralph Kästner +6 more
Journal ArticleDOI
Risk of postpartum depressive symptoms is influenced by psychological burden related to the COVID-19 pandemic and dependent of individual stress coping
S Meister,Eva-Maria Dreyer,Laura Hahn,Marilena Thomann,L. Keilmann,Susanne Beyer,Clarissa Mayer,Gwendolin Prins,Uwe Hasbargen,Sven Mahner,Udo Jeschke,Thomas Kolben,Alexander Burges +12 more
TL;DR: In this paper , a modified version of the stress and coping inventory (SCI) and the Edinburgh Postnatal Depression Scale (EPDS) was used to evaluate the psychological burden related to the COVID-19 pandemic with the risk of developing postpartum depressive symptoms.
Journal ArticleDOI
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Linn Woelber,Monika Hampl,Christine Eulenburg,Katharina Prieske,J. Hambrecht,Sophie Fuerst,R Klapdor,Sabine Heublein,Paul Gass,Annika Rohner,Ulrich Canzler,Sven Becker,Mareike Bommert,Dirk Bauerschlag,Agnieszka Denecke,Lars Hanker,Ingo Runnebaumn,Dirk Forner,Fabienne Schochter,Maximilian Klar,R Schwab,Melitta Koepke,Matthias Kalder,Peer Hantschmann,Dominik Ratiu,Dominik Denschlag,W. Schroeder,Benjamin Tuschy,Klaus Baumann,Alexander Mustea,Philipp Soergel,Holger Bronger,Gerd J. Bauerschmitz,J Kosse,Martin Koch,Atanas Ignatov,Jalid Sehouli,Christian Dannecker,Sven Mahner,Anna Jaeger +39 more
TL;DR: The study aims to describe the risk for pelvic lymph node metastasis with regard to positive groin nodes and to clarify the indication criteria for pelvic treatment in node-positive vulvar cancer, finding that a relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher.
Journal ArticleDOI
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Fabian Trillsch,Fabienne Schochter,Tjoung-Won Park-Simon,Alexander Reuss,Tanja Fehm,Pauline Wimberger,Holger Bronger,Barbara Schmalfeldt,Jalid Sehouli,Frederik Marmé,Florian Heitz,Sven Mahner,M. F. Fredrich,Stefanie Barth,James Stec,Michael Method,Philipp Harter +16 more
TL;DR: The antibody-drug conjugate Mirvetuximab soravtansine (MIRV) is comprised of a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent, which is well-tolerated with a manageable safety profile.
Journal ArticleDOI
Updates of placental macrophages: Origins, molecular markers, functions, and related diseases.
Huixia Yang,Anca Chelariu-Raicu,D. Makri,Chaido Ori,Pedro Cristiano Pinto Ribeiro,Thomas Kolben,Christian Kuhn,Mirjana Kessler,Christian Schulz,Sven Mahner,Udo Jeschke,Viktoria von Schönfeldt +11 more
TL;DR: In this paper , a review summarizes recent findings on the cellular origin of placental macrophages, and provides a comprehensive description of their phenotypes, corresponding molecular markers and functions in human placenta.